The United States of America, As Represented by the Secretary, Department of Health and Human Services

Luigi Ferrucci

Ruin Moaddel

Lorah Perlee

Christopher E Ramsden

Gregory S Keyes

Velizar T Tchernev

Serguei Lejnine

Kotb Abdelmohsen

Myriam Gorospe

Shari M Ling

Dhavalkumar D Patel

Martina Rossi

Ming Zhan

Gingerenone A prodrug compounds have a structure according to Formula I, or a pharmaceutically acceptable salt thereof wherein one of Rand Ris H or —C(O)—R and the other of Rand Ris —C(O)—R. Each R independently is Ror, where Ris C-Calkenyl, and Ris an amino acid side chain. The compounds are useful for inhibiting or eliminating senescence. The compounds may be administered to a subject having a senescence-associated disease or disorder, neuroinflammation, pain, and/or an amino acid deficiency.

Gingerenone A prodrugs as sensotherapeutics and methods of use

Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.

Methods for evaluating osteoarthritis risk

Growing community of inventors

Baltimore, MD, United States of America

Luigi Ferrucci